Please Wait.....
Report
Biosurgery Market by Product (Bone Graft Substitutes, Sealants (Natural (Gelatin, Collagen)), Hemostatic Agents, Soft-tissue Attachments (Synthetic, Biological)), Application (Orthopedic, Urological), End User (Hospitals, ASCs) - Global Forecast to 2030
Market Report I 2025-07-28 I 414 Pages I MarketsandMarkets
The global biosurgery market is projected to reach USD 21.59 million by 2030 from USD 15.83 million in 2025, at a CAGR of 6.4% during the forecast period. The biosurgery market is experiencing robust growth, propelled by several key dynamics. A primary driver is the increasing prevalence of chronic conditions that necessitate surgical interventions, alongside a rise in severe traumatic injuries. As these incidents become more common, there is a corresponding uptick in the volume of elective surgical procedures, subsequently fueling the demand for biosurgical products. Moreover, the escalating need for efficient blood loss management and the enhanced availability of advanced biosurgical technologies further support market expansion. However, this growth trajectory faces challenges, including the high cost associated with biosurgery products, a shortage of adequately skilled professionals, and a stringent regulatory environment, all of which are anticipated to hinder the market's progress over the forecast period.
https://www.marketsandmarkets.com/Images/biosurgery-market-Overview.webp
The demineralized bone matrix subsegment, by bone graft substitutes, held the largest market share in 2024.
Based on product, the biosurgery market is divided into bone-graft substitutes, soft-tissue attachments, hemostatic agents, surgical sealants and adhesives, adhesion barriers, and staple-line reinforcement agents. In 2024, the bone graft substitute market was predominantly led by the demineralized bone matrix (DBM) segment, which is recognized for its dual osteoconductive and osteoinductive properties, thereby facilitating effective bone regeneration. Within the broader category of bone graft substitutes-which includes synthetic grafts, bone morphogenetic proteins (BMPs), and other alternatives-DBM has emerged as the most significant player in the biosurgery sector. DBM is extensively employed in various orthopedic procedures, such as spinal fusion and hip & knee replacements, owing to its enhanced clinical efficacy in promoting bone healing. Its versatility is further accentuated by its availability in multiple forms, including pastes, putty, sheets, and flexible fragments, allowing for tailored surgical applications. The process of creating DBM involves the removal of inorganic minerals from allograft bones, which unveils BMPs that actively stimulate osteogenesis. This characteristic positions DBM as a reliable and biologically active substitute for autografts. Furthermore, implementing terminal sterilization techniques, such as gamma irradiation and electron-beam sterilization, ensures the safety and integrity of the product. The sustained preference of surgeons for DBM as a safe, effective, and accessible graft substitute continues to reinforce its leading status within this market segment.
The ambulatory surgical centers of the biosurgery end user market are expected to command the highest CAGR during the study period.
The biosurgery market, based on end users, is divided into ambulatory surgical centers (ASCs), hospitals, clinics, and other end users. The ambulatory surgical centers (ASCs) segment is anticipated to lead growth in the biosurgery market throughout the forecast period. This expansion is underpinned by an increasing demand for cost-effective, efficient, and minimally invasive surgical options. ASCs present an economically viable alternative to traditional hospitals while upholding high standards for surgical safety and clinical outcomes, making them increasingly appealing to patients and healthcare practitioners. These centers are optimally equipped to perform various outpatient procedures, including orthopedic, ophthalmic, cosmetic, and general surgeries. In these settings, biosurgical products such as sealants, hemostats, and adhesion barriers are critical in enhancing surgical precision and promoting patient recovery. Advancements in surgical techniques, anesthesia, and biosurgical technologies accelerate the ongoing transition of surgical volumes from inpatient environments to outpatient facilities. Factors such as rising healthcare expenditures, advantageous reimbursement policies for outpatient procedures, and reduced patient recovery times are further driving the growth of ASCs. As patient preferences increasingly lean toward expedited, same-day procedures with a minimized risk of hospital-acquired infections, the demand for biosurgical solutions in ASCs is projected to escalate, thus propelling rapid growth in this segment.
In 2024, the North America region accounted for the largest share in the biosurgery market.
The global biosurgery market is segmented into five major regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2024, the North American region is projected to maintain the largest share of the global biosurgery market, attributable to its sophisticated healthcare infrastructure, elevated surgical rates, and the concentration of prominent industry players. This region has experienced notable increases in cosmetic and reconstructive surgeries and a marked rise in orthopedic procedures. According to Discovery ABA, approximately 26.2 million surgical and minimally invasive cosmetic and reconstructive procedures were performed in the United States in 2022, reflecting a 19% increase in cosmetic surgeries compared to 2019. Furthermore, the 2022 data from the American Joint Replacement Registry (AJRR) highlights over 2.8 million hip and knee procedures conducted across all 50 states and the District of Columbia, underscoring the significant demand for biosurgery products in joint replacement and orthopedic applications. Key drivers for this market expansion include a growing geriatric population, a high incidence of chronic diseases, and an increasing volume of surgical interventions necessitating advanced hemostatic agents, sealants, and materials for soft tissue repair. Coupled with favorable reimbursement frameworks, heightened patient awareness, and substantial R&D investments from leading companies such as Johnson & Johnson, Baxter, and Stryker, North America is solidifying its position as the most dominant and mature biosurgery market globally.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1- 40%, Tier 2- 30%, and Tier 3- 30%
- By Designation: C-level- 50%, Director level- 30%, and Others- 20%
- By Region: North America- 30%, Europe- 25%, Asia Pacific- 20%, Latin America- 15%, and Middle East & Africa- 10%.
Note 1: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.0 billion, Tier 2 = USD 1.0 billion to USD 10.0 billion, and Tier 3 =
Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
The players operating in the biosurgery market include Johnson & Johnson Services, Inc. (US), Baxter (US), Medtronic (Ireland), Becton, Dickinson and Company (BD) (US), B. Braun Melsungen AG (Germany), Stryker (US), Integra Lifesciences Holdings Corporation (US), CSL Ltd. (Australia), Hemostasis LLC. (US), Pfizer Inc. (US), Artivion Inc. (US), Zimmer Biomet (US), Kuros Biosciences AG (Switzerland), Orthofix Medical Inc. (US), Smiths & Nephew PLC (UK), Tissue Regenix (UK), Betatech Medical (Turkey), Meril Lifesciences Pvt. Ltd. (India), RTI Surgicals (US), Samyang Holdings Corp. (South Korea), Aroa Biosurgery Ltd. (New Zealand), Meyer-Haake GmbH (Germany), Advanced Medical Solutions Group PLC (UK), BioCer Entwicklungs-GmbH (Germany), and Hannox International Corp. (Taiwan)
Research Coverage
This report studies the biosurgery market based on product, application, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets concerning their growth trends. It forecasts the revenue of the market segments concerning five major regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established and entrants/smaller firms to gauge the market's pulse, which, in turn, would help them gain a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.
This report provides insights on the following pointers:
- Analysis of key drivers (increasing volume of surgeries and growing prevalence of severe trauma injuries, strong focus on R&D leading to launch of technologically advanced products, and rising need for effective blood loss management in patients), restraints (high price of biosurgery products and rising cost of surgical procedures), opportunities (increasing use of combination materials for enhancing product efficacy, rising adoption of advanced biosurgery products in emerging markets, and growing adoption of adhesive dentistry procedures), challenges (stringent regulatory framework and requirement of skilled personnel for the effective use of biosurgery products)
- Market Penetration: Complete knowledge of the spectrum of products presented by the major companies in the biosurgery market
- Product Development/Innovation: Comprehensive understanding of the forthcoming trends, R&D initiatives, and product launches within the biosurgery market
- Market Development: Complete knowledge about profitable developing regions
- Market Diversification: Exhaustive knowledge of new goods, expanding geographies, and current changes in the biosurgery industry help to diversify the market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Johnson & Johnson Services, Inc. (US), Baxter (US), Medtronic (Ireland), Becton Dickinson and Company (BD) (US), B. Braun SE (Germany), Stryker (US), Integra LifeSciences Holdings Corporation (US), CSL Ltd. (Australia), Hemostasis LLC. (US), Pfizer Inc. (US), Artivion Inc. (US), and others.
1 INTRODUCTION 36
1.1 STUDY OBJECTIVES 36
1.2 MARKET DEFINITION 36
1.3 STUDY SCOPE 37
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 37
1.3.2 INCLUSIONS & EXCLUSIONS 38
1.3.3 YEARS CONSIDERED 39
1.3.4 CURRENCY CONSIDERED 40
1.4 STAKEHOLDERS 40
1.5 SUMMARY OF CHANGES 41
2 RESEARCH METHODOLOGY 42
2.1 RESEARCH DATA 42
2.1.1 SECONDARY DATA 42
2.1.1.1 Key objectives of secondary research 43
2.1.1.2 List of key secondary sources 43
2.1.1.3 Key data from secondary sources 44
2.1.2 PRIMARY DATA 44
2.1.2.1 Key objectives of primary research 45
2.1.2.2 Key data from primary sources 46
2.1.2.3 Key industry insights 47
2.2 MARKET SIZE ESTIMATION 48
2.2.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS) 48
2.2.2 TOP-DOWN APPROACH 49
2.2.3 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS 49
2.2.4 GROWTH FORECAST 49
2.3 DATA TRIANGULATION 52
2.4 MARKET RANKING ANALYSIS 52
2.5 STUDY ASSUMPTIONS 53
2.6 RESEARCH LIMITATIONS 53
2.6.1 METHODOLOGY-RELATED LIMITATIONS 53
2.6.2 SCOPE-RELATED LIMITATIONS 53
2.7 RISK ANALYSIS 54
3 EXECUTIVE SUMMARY 55
?
4 PREMIUM INSIGHTS 59
4.1 BIOSURGERY MARKET OVERVIEW 59
4.2 NORTH AMERICA: BIOSURGERY MARKET, BY COUNTRY AND END USER 60
4.3 GEOGRAPHIC SNAPSHOT OF BIOSURGERY MARKET 61
4.4 REGIONAL MIX: BIOSURGERY MARKET, 2025-2030 (USD MILLION) 61
4.5 BIOSURGERY MARKET: EMERGING VS. DEVELOPED MARKETS,
2025 VS. 2030 (USD MILLION) 62
5 MARKET OVERVIEW 63
5.1 INTRODUCTION 63
5.2 MARKET DYNAMICS 63
5.2.1 DRIVERS 64
5.2.1.1 Increasing volume of surgeries and growing prevalence of severe trauma injuries 64
5.2.1.2 Rising need for effective blood loss management 64
5.2.2 RESTRAINTS 64
5.2.2.1 High price of biosurgery products and surgical procedures 64
5.2.3 OPPORTUNITIES 65
5.2.3.1 Rising use of combination materials for enhancing product efficacy 65
5.2.3.2 Growing adoption of adhesive dentistry procedures 65
5.2.4 CHALLENGES 65
5.2.4.1 Stringent regulatory framework 65
5.2.4.2 Scarcity of skilled personnel for effective use of biosurgery products 66
5.3 TECHNOLOGY ANALYSIS 66
5.3.1 KEY TECHNOLOGIES 66
5.3.1.1 Hemostatic & sealant biomaterial technology 66
5.3.1.2 Tissue engineering & regenerative medicine technology 67
5.3.2 COMPLEMENTARY TECHNOLOGIES 67
5.3.2.1 Surgical imaging & navigation technology 67
5.3.2.2 Sterilization & preservation technology 67
5.3.3 ADJACENT TECHNOLOGIES 68
5.3.3.1 3D printing technology 68
5.3.3.2 Minimally invasive technology 68
5.4 INDUSTRY TRENDS 68
5.4.1 GROWING PREFERENCE FOR GELATIN-BASED ADHESIVES &
HYDROGELS IN SURGICAL PROCEDURES 68
5.4.2 USE OF NANOTECHNOLOGY FOR DEVELOPING NEXT-GENERATION ADHESIVES 69
5.5 VALUE CHAIN ANALYSIS 69
5.6 ECOSYSTEM ANALYSIS 70
5.7 SUPPLY CHAIN ANALYSIS 71
5.8 TRADE ANALYSIS 72
5.8.1 IMPORT DATA FOR HS CODE 300610, 2019-2024 72
5.8.2 EXPORT DATA FOR HS CODE 300610, 2019-2024 72
5.9 PORTER'S FIVE FORCES ANALYSIS 73
5.9.1 THREAT OF NEW ENTRANTS 74
5.9.2 THREAT OF SUBSTITUTES 74
5.9.3 BARGAINING POWER OF BUYERS 75
5.9.4 BARGAINING POWER OF SUPPLIERS 75
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 75
5.10 KEY STAKEHOLDERS & BUYING CRITERIA 75
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 75
5.10.2 KEY BUYING CRITERIA 76
5.11 REGULATORY ANALYSIS 77
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78
5.11.2 REGULATORY ANALYSIS 80
5.11.2.1 North America 80
5.11.2.1.1 US 80
5.11.2.1.2 Canada 80
5.11.2.2 Europe 81
5.11.2.3 Asia Pacific 81
5.11.2.4 Latin America 82
5.11.2.5 Middle East & Africa 82
5.12 PATENT ANALYSIS 82
5.12.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 84
5.13 PRICING ANALYSIS 84
5.13.1 AVERAGE SELLING PRICE TREND OF BIOSURGERY PRODUCTS,
BY KEY PLAYER, 2022-2024 84
5.13.2 AVERAGE SELLING PRICE TREND OF BIOSURGERY PRODUCTS,
BY REGION, 2022-2024 85
5.14 KEY CONFERENCES & EVENTS, 2025-2026 86
5.15 ADJACENT MARKET ANALYSIS 87
5.15.1 ADHESION BARRIERS MARKET 87
5.16 UNMET NEEDS/END-USER EXPECTATIONS 88
5.17 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS 89
5.18 INVESTMENT & FUNDING SCENARIO 89
5.19 IMPACT OF AI/GEN AI ON BIOSURGERY MARKET 90
5.20 IMPACT OF 2025 US TARIFF ON BIOSURGERY MARKET 91
5.20.1 INTRODUCTION 91
5.20.2 KEY TARIFF RATES 92
5.20.3 PRICE IMPACT ANALYSIS 93
5.20.4 IMPACT ON COUNTRIES/REGIONS 93
5.20.4.1 North America 93
5.20.4.1.1 US 93
?
5.20.4.2 Europe 94
5.20.4.3 Asia Pacific 94
5.20.5 IMPACT ON END-USE INDUSTRIES 94
6 BIOSURGERY MARKET, BY PRODUCT 95
6.1 INTRODUCTION 96
6.2 BONE-GRAFT SUBSTITUTES 97
6.2.1 DEMINERALIZED BONE MATRIX 98
6.2.1.1 Rising volume of spinal fusion, joint reconstruction, and replacement surgeries to drive segment 98
6.2.2 SYNTHETIC BONE GRAFTS 100
6.2.2.1 High compressive strength, osteoconductive properties, and minimal risk of disease transmission to fuel segment growth 100
6.2.3 BONE MORPHOGENETIC PROTEINS 102
6.2.3.1 Increasing prevalence of spinal deformities, disc degeneration, trauma, and sport-related injuries to propel segment growth 102
6.2.4 OTHER BONE-GRAFT SUBSTITUTES 103
6.3 SURGICAL SEALANTS & ADHESIVES 105
6.3.1 NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES 107
6.3.1.1 Natural/Biological surgical sealants & adhesives, by type 108
6.3.1.1.1 Fibrin-based sealants & adhesives 109
6.3.1.1.1.1 Biocompatibility, biodegradability, and effectiveness in achieving hemostasis to augment segment growth 109
6.3.1.1.2 Collagen-based sealants & adhesives 111
6.3.1.1.2.1 Low-cost and reduced risk of disease transmission to promote adoption of collagen-based sealants & adhesives 111
6.3.1.1.3 Gelatin-based sealants & adhesives 113
6.3.1.1.3.1 High elasticity, strong adhesive properties, and versatility in soft tissue applications to boost segment growth 113
6.3.1.1.4 Albumin-based sealants & adhesives 115
6.3.1.1.4.1 Increasing adoption in cardiovascular and cardiothoracic procedures to fuel market growth 115
6.3.1.1.5 Other natural/biological surgical sealants & adhesives 116
6.3.1.2 Natural/biological surgical sealants & adhesives, by origin 118
6.3.1.2.1 Animal-based sealants & adhesives 118
6.3.1.2.1.1 Ease of usage, better flexibility, and greater strength to boost adoption in medical applications 118
6.3.1.2.2 Human blood-based sealants & adhesives 119
6.3.1.2.2.1 Human blood-based sealants to be used in final stage of clotting cascade for local and diffused hemorrhages 119
6.3.2 SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES 120
6.3.2.1 PEG hydrogel-based sealants & adhesives 123
6.3.2.1.1 Rapid sealing abilities of PEG hydrogels to drive adoption in spinal surgeries 123
?
6.3.2.2 Cyanoacrylate-based sealants & adhesives 125
6.3.2.2.1 Cyanoacrylate-based sealants to be preferred in dermatology and plastic surgeries 125
6.3.2.3 Urethane-based sealants & adhesives 126
6.3.2.3.1 Favorable thermostable property at body temperature without hemolytic behavior to drive segment 126
6.3.2.4 Other synthetic & semi-synthetic surgical sealants & adhesives 128
6.4 ADHESION BARRIERS 129
6.4.1 SYNTHETIC ADHESION BARRIERS 131
6.4.1.1 Hyaluronic acid-based adhesion barriers 133
6.4.1.1.1 Rising gynecological and abdominal surgeries to fuel adoption 133
6.4.1.2 Regenerated cellulose-based adhesion barriers 134
6.4.1.2.1 Increasing number of C-section surgeries to boost adoption of regenerated cellulose-based adhesion barriers 134
6.4.1.3 PEG-based adhesion barriers 136
6.4.1.3.1 Rising number of peritoneal and abdominal surgeries to drive demand 136
6.4.1.4 Other synthetic adhesion barriers 137
6.4.2 NATURAL ADHESION BARRIERS 138
6.4.2.1 Collagen & protein adhesion barriers 139
6.4.2.1.1 Weak antigenicity, high biocompatibility, non-toxicity, and biodegradability to propel segment growth 139
6.4.2.2 Fibrin-based adhesion barriers 140
6.4.2.2.1 Increasing applications in laparotomy procedures to spur segment growth 140
6.5 STAPLE-LINE REINFORCEMENT AGENTS 142
6.5.1 RISING VOLUME OF COMPLEX SURGICAL PROCEDURRES TO DRIVE MARKET 142
6.6 SOFT-TISSUE ATTACHMENTS 143
6.6.1 SYNTHETIC MESHES 145
6.6.1.1 Increasing demand for safe and cost-effective soft tissue reinforcement to drive segment 145
6.6.2 BIOLOGICAL MESHES 146
6.6.2.1 Allografts 148
6.6.2.1.1 Rising cancer incidence and reconstructive surgeries to increase adoption of allografts in biosurgical procedures 148
6.6.2.2 Xenografts 149
6.6.2.2.1 High availability and size versatility to drive segmental growth 149
6.7 HEMOSTATIC AGENTS 150
6.7.1 THROMBIN-BASED HEMOSTATIC AGENTS 152
6.7.1.1 Rising demand for safer and fast-acting clotting agents to drive growth of thrombin-based hemostats 152
6.7.2 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATIC AGENTS 154
6.7.2.1 Rising adoption of plant-based and absorbable hemostats to propel segment growth 154
6.7.3 COMBINATION HEMOSTATIC AGENTS 155
6.7.3.1 Superior efficacy in complex bleeding control to drive adoption of combination hemostatic agents globally 155
7 BIOSURGERY MARKET, BY APPLICATION 157
7.1 INTRODUCTION 158
7.2 ORTHOPEDIC SURGERY 158
7.2.1 INCREASING INCIDENCE OF SPORTS INJURIES AND GROWING PREVALENCE OF OSTEOPOROSIS TO PROPEL MARKET GROWTH 158
7.3 GENERAL SURGERY 160
7.3.1 HIGH GERIATRIC POPULATION AND INCREASED PREVALENCE OF OBESITY TO FUEL DEMAND FOR BARIATRIC INTERVENTIONS 160
7.4 NEUROLOGICAL SURGERY 162
7.4.1 GROWING PREVALENCE OF NEUROLOGICAL DISORDERS TO AUGMENT MARKET GROWTH 162
7.5 CARDIOVASCULAR SURGERY 163
7.5.1 BIOSURGERY PRODUCTS TO REPLACE CONVENTIONAL SUTURE-BASED METHODS IN CARDIOVASCULAR PROCEDURES 163
7.6 RECONSTRUCTIVE SURGERY 165
7.6.1 INCREASING FACIAL COSMETIC SURGERIES AND BREAST RECONSTRUCTION PROCEDURES TO PROPEL MARKET GROWTH 165
7.7 GYNECOLOGICAL SURGERY 166
7.7.1 COMPLEXITY OF GYNECOLOGICAL PROCEDURES TO FUEL DEMAND FOR ADVANCED BIOSURGICAL PRODUCTS 166
7.8 UROLOGICAL SURGERY 168
7.8.1 USE OF BIOSURGERY PRODUCTS IN COMPLEX RECONSTRUCTIVE UROLOGICAL SURGERIES TO STIMULATE SEGMENT GROWTH 168
7.9 THORACIC SURGERY 169
7.9.1 RISING INCIDENCE OF PULMONARY CHRONIC DISEASES TO SPUR MARKET GROWTH 169
7.10 OTHER APPLICATIONS 171
8 BIOSURGERY MARKET, BY END USER 173
8.1 INTRODUCTION 174
8.2 HOSPITALS 174
8.2.1 RISING NUMBER OF REIMBURSED INPATIENT PROCEDURES TO DRIVE POPULARITY OF HOSPITALS FOR SURGERIES 174
8.3 CLINICS 176
8.3.1 QUICKER CONSULTATION SERVICES AND MINIMAL PATIENT STAYS TO FAVOR MARKET GROWTH 176
8.4 AMBULATORY SURGICAL CENTERS 177
8.4.1 RISING DEMAND FOR COST-EFFECTIVE SAME-DAY SURGERIES TO AUGMENT MARKET GROWTH 177
8.5 OTHER END USERS 178
?
9 BIOSURGERY MARKET, BY REGION 180
9.1 INTRODUCTION 181
9.2 NORTH AMERICA 182
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 182
9.2.2 US 189
9.2.2.1 US to dominate North American biosurgery market during forecast period 189
9.2.3 CANADA 195
9.2.3.1 Growing prevalence of chronic diseases to drive market 195
9.3 EUROPE 201
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 207
9.3.2 GERMANY 207
9.3.2.1 Robust healthcare investments and improved infrastructure to support adoption of advanced surgical technologies 207
9.3.3 UK 213
9.3.3.1 Rise in popularity of cosmetic and reconstructive surgeries to fuel market growth 213
9.3.4 FRANCE 219
9.3.4.1 Presence of well-established healthcare system and high geriatric population to boost market growth 219
9.3.5 ITALY 225
9.3.5.1 Increasing surgical volume to fuel market growth 225
9.3.6 SPAIN 231
9.3.6.1 Rising surgical demand to boost need for biosurgery products 231
9.3.7 REST OF EUROPE 237
9.4 ASIA PACIFIC 243
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 243
9.4.2 CHINA 251
9.4.2.1 Increasing number of domestic biosurgery and medical device manufacturers to aid market growth 251
9.4.3 INDIA 257
9.4.3.1 Rising healthcare awareness and favorable government support to stimulate market growth 257
9.4.4 JAPAN 263
9.4.4.1 Advanced healthcare system and high geriatric population to spur market growth 263
9.4.5 SOUTH KOREA 269
9.4.5.1 Rising number of cosmetic surgeries and growing adoption of innovative medical technologies to drive market 269
9.4.6 AUSTRALIA 275
9.4.6.1 Well-established healthcare system and high government medical expenditure to favor market growth 275
9.4.7 REST OF ASIA PACIFIC 281
?
9.5 LATIN AMERICA 288
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 288
9.5.2 BRAZIL 294
9.5.2.1 Rapidly aging population and high prevalence of chronic diseases to support market growth 294
9.5.3 MEXICO 300
9.5.3.1 Enhanced focus on medical tourism to drive market 300
9.5.4 REST OF LATIN AMERICA 306
9.6 MIDDLE EAST & AFRICA 313
9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 313
9.6.2 GCC COUNTRIES 319
9.6.2.1 Rising prevalence of chronic diseases to drive market 319
9.6.3 REST OF MIDDLE EAST & AFRICA 325
10 COMPETITIVE LANDSCAPE 332
10.1 INTRODUCTION 332
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 332
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOSURGERY MARKET 332
10.3 REVENUE ANALYSIS, 2020-2024 334
10.4 MARKET SHARE ANALYSIS, 2024 334
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 336
10.5.1 STARS 336
10.5.2 EMERGING LEADERS 336
10.5.3 PERVASIVE PLAYERS 337
10.5.4 PARTICIPANTS 337
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 338
10.5.5.1 Company footprint 338
10.5.5.2 Region footprint 339
10.5.5.3 Product footprint 340
10.5.5.4 Application footprint 341
10.5.5.5 End-user footprint 342
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 343
10.6.1 PROGRESSIVE COMPANIES 343
10.6.2 RESPONSIVE COMPANIES 343
10.6.3 DYNAMIC COMPANIES 343
10.6.4 STARTING BLOCKS 343
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 345
10.6.5.1 Detailed list of key startups/SMEs 345
10.6.5.2 Competitive benchmarking of key startups/SMEs 346
10.7 COMPANY VALUATION & FINANCIAL METRICS 347
10.7.1 FINANCIAL METRICS 347
10.7.2 COMPANY VALUATION 347
10.8 BRAND/PRODUCT COMPARISON 348
10.9 COMPETITIVE SCENARIO 348
10.9.1 PRODUCT LAUNCHES & APPROVALS 348
10.9.2 DEALS 349
11 COMPANY PROFILES 350
11.1 KEY PLAYERS 350
11.1.1 BAXTER 350
11.1.1.1 Business overview 350
11.1.1.2 Products offered 351
11.1.1.3 MnM view 352
11.1.1.3.1 Key strengths 352
11.1.1.3.2 Strategic choices 353
11.1.1.3.3 Weaknesses & competitive threats 353
11.1.2 B. BRAUN SE 354
11.1.2.1 Business overview 354
11.1.2.2 Products offered 355
11.1.2.3 MnM view 356
11.1.2.3.1 Key strengths 356
11.1.2.3.2 Strategic choices 356
11.1.2.3.3 Weaknesses & competitive threats 356
11.1.3 BECTON, DICKINSON AND COMPANY (BD) 357
11.1.3.1 Business overview 357
11.1.3.2 Products offered 358
11.1.3.3 MnM view 360
11.1.3.3.1 Key strengths 360
11.1.3.3.2 Strategic choices 360
11.1.3.3.3 Weaknesses & competitive threats 360
11.1.4 JOHNSON & JOHNSON 361
11.1.4.1 Business overview 361
11.1.4.2 Products offered 362
11.1.4.3 MnM view 363
11.1.4.3.1 Key strengths 363
11.1.4.3.2 Strategic choices 363
11.1.4.3.3 Weaknesses & competitive threats 364
11.1.5 MEDTRONIC 365
11.1.5.1 Business overview 365
11.1.5.2 Products offered 366
11.1.5.3 MnM view 367
11.1.5.3.1 Key strengths 367
11.1.5.3.2 Strategic choices 367
11.1.5.3.3 Weaknesses & competitive threats 368
11.1.6 INTEGRA LIFESCIENCES CORPORATION 369
11.1.6.1 Business overview 369
11.1.6.2 Products offered 370
11.1.7 COMMONWEALTH SERUM LABORATORIES LIMITED (CSL) 372
11.1.7.1 Business overview 372
11.1.7.2 Products offered 373
11.1.8 HEMOSTASIS, LLC 374
11.1.8.1 Business overview 374
11.1.8.2 Products offered 374
11.1.9 PFIZER INC. 375
11.1.9.1 Business overview 375
11.1.9.2 Products offered 376
11.1.10 STRYKER 377
11.1.10.1 Business overview 377
11.1.10.2 Products offered 378
11.1.11 ARTIVION, INC. 380
11.1.11.1 Business overview 380
11.1.11.2 Products offered 381
11.1.12 ZIMMER BIOMET 383
11.1.12.1 Business overview 383
11.1.12.2 Products offered 384
11.1.12.3 Recent developments 385
11.1.12.3.1 Deals 385
11.1.13 KUROS BIOSCIENCES 386
11.1.13.1 Business overview 386
11.1.13.2 Products offered 387
11.1.13.3 Recent developments 387
11.1.13.3.1 Product approvals 387
11.1.13.3.2 Deals 388
11.1.14 ORTHOFIX MEDICAL INC. 389
11.1.14.1 Business overview 389
11.1.14.2 Products offered 390
11.1.14.3 Recent developments 391
11.1.14.3.1 Product launches 391
11.1.14.3.2 Deals 391
11.1.15 SMITH & NEPHEW 392
11.1.15.1 Business overview 392
11.1.15.2 Products offered 393
11.2 OTHER PLAYERS 394
11.2.1 TISSUE REGENIX 394
11.2.2 BETATECH MEDICAL 395
11.2.3 MERIL LIFE SCIENCES PVT. LTD. 396
11.2.4 GLOBUS MEDICAL 397
11.2.5 SAMYANG HOLDINGS CORPORATION 398
11.2.6 AROA BIOSURGERY LIMITED 399
11.2.7 MEYER-HAAKE GMBH 400
11.2.8 ADVANCED MEDICAL SOLUTIONS GROUP PLC 401
11.2.9 BIOCER ENTWICKLUNGS-GMBH 402
11.2.10 WILTROM 403
12 APPENDIX 404
12.1 DISCUSSION GUIDE 404
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 410
12.3 CUSTOMIZATION OPTIONS 412
12.4 RELATED REPORTS 412
12.5 AUTHOR DETAILS 413
TABLE 1 BIOSURGERY MARKET: INCLUSIONS & EXCLUSIONS 38
TABLE 2 STANDARD CURRENCY CONVERSION RATES 40
TABLE 3 BIOSURGERY MARKET: STUDY ASSUMPTIONS 53
TABLE 4 BIOSURGERY MARKET: RISK ANALYSIS 54
TABLE 5 IMPORT DATA FOR HS CODE 300610, BY COUNTRY,
2019-2024 (USD THOUSAND) 72
TABLE 6 EXPORT DATA FOR HS CODE 300610, BY COUNTRY,
2019-2024 (USD THOUSAND) 73
TABLE 7 BIOSURGERY MARKET: PORTER'S FIVE FORCES 73
TABLE 8 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP THREE BIOSURGERY PRODUCTS 76
TABLE 9 KEY BUYING CRITERIA FOR BIOSURGERY PRODUCTS 77
TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78
TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78
TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 13 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 14 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 15 AVERAGE SELLING PRICE TREND OF BIOSURGERY PRODUCTS, BY KEY PLAYER, 2022-2024 (USD) 85
TABLE 16 AVERAGE SELLING PRICE TREND OF BIOSURGERY PRODUCTS, BY REGION,
2022-2024 (USD) 85
TABLE 17 BIOSURGERY MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS,
JANUARY 2025-DECEMBER 2026 86
TABLE 18 BIOSURGERY MARKET: UNMET NEEDS/END-USER EXPECTATIONS 88
TABLE 19 US-ADJUSTED RECIPROCAL TARIFF RATES 92
TABLE 20 KEY PRODUCT-RELATED TARIFF EFFECTIVE FOR BIOSURGERY PRODUCTS 93
TABLE 21 BIOSURGERY MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 96
TABLE 22 BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,
2023-2030 (USD MILLION) 97
TABLE 23 BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY COUNTRY,
2023-2030 (USD MILLION) 98
TABLE 24 MAJOR DEMINERALIZED BONE MATRIX PRODUCTS AVAILABLE IN MARKET 99
TABLE 25 DEMINERALIZED BONE MATRIX MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 100
TABLE 26 MAJOR SYNTHETIC BONE GRAFTS AVAILABLE IN MARKET 101
TABLE 27 SYNTHETIC BONE GRAFTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 101
TABLE 28 MAJOR BONE MORPHOGENETIC PROTEINS AVAILABLE IN MARKET 102
TABLE 29 BONE MORPHOGENETIC PROTEINS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 103
TABLE 30 OTHER BONE-GRAFT SUBSTITUTES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 105
TABLE 31 BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE,
2023-2030 (USD MILLION) 106
TABLE 32 BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY COUNTRY, 2023-2030 (USD MILLION) 107
TABLE 33 NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 108
TABLE 34 NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 109
TABLE 35 MAJOR FIBRIN-BASED SEALANTS & ADHESIVES AVAILABLE IN MARKET 110
TABLE 36 FIBRIN-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 111
TABLE 37 MAJOR COLLAGEN BASED-SEALANTS & ADHESIVES AVAILABLE IN MARKET 112
TABLE 38 COLLEGEN-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 113
TABLE 39 MAJOR GELATIN BASED-SEALANTS & ADHESIVES AVAILABLE IN MARKET 114
TABLE 40 GELATIN-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 114
TABLE 41 MAJOR ALBUMIN BASED-SEALANTS & ADHESIVES AVAILABLE IN MARKET 115
TABLE 42 ALBUMIN-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 116
TABLE 43 OTHER NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 117
TABLE 44 NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023-2030 (USD MILLION) 118
TABLE 45 ANIMAL-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 119
TABLE 46 HUMAN BLOOD-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 120
TABLE 47 SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET,
BY TYPE, 2023-2030 (USD MILLION) 121
TABLE 48 SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 122
TABLE 49 MAJOR PRODUCTS PEG HYDROGEL-BASED SEALANTS & ADHESIVES AVAILABLE IN MARKET 123
TABLE 50 PEG HYROGEL-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 124
TABLE 51 MAJOR CYANOACRYLATE-BASED SEALANTS & ADHESIVES AVAILABLE IN MARKET 125
TABLE 52 CYANOACRYLATE-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 126
TABLE 53 URETHANE-BASED SEALANTS & ADHESIVES MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 127
TABLE 54 OTHER SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 129
TABLE 55 BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,
2023-2030 (USD MILLION) 130
TABLE 56 BIOSURGERY MARKET FOR ADHESION BARRIERS, BY COUNTRY,
2023-2030 (USD MILLION) 130
TABLE 57 SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 131
TABLE 58 SYNTHETIC ADHESION BARRIERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 132
TABLE 59 MAJOR HYALURONIC ACID-BASED ADHESION BARRIERS AVAILABLE IN MARKET 133
TABLE 60 HYALURONIC ACID-BASED ADHESION BARRIERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 134
TABLE 61 MAJOR REGENERATED CELLULOSE-BASED ADHESION BARRIERS AVAILABLE IN MARKET 135
TABLE 62 REGENERATED CELLULOSE -BASED ADHESION BARRIERS MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 135
TABLE 63 MAJOR PEG-BASED ADHESION BARRIERS AVAILABLE IN MARKET 136
TABLE 64 PEG-BASED ADHESION BARRIERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 137
TABLE 65 OTHER SYNTHETIC ADHESION BARRIERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 138
TABLE 66 NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 139
TABLE 67 MAJOR COLLAGEN & PROTEIN ADHESION BARRIERS AVAILABLE IN MARKET 139
TABLE 68 COLLAGEN & PROTEIN ADHESION BARRIERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 140
TABLE 69 MAJOR FIBRIN-BASED ADHESION BARRIERS AVAILABLE IN MARKET 141
TABLE 70 FIBRIN-BASED ADHESION BARRIERS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 141
TABLE 71 MAJOR STAPLE-LINE REINFORCEMENT AGENTS AVAILABLE IN MARKET 142
TABLE 72 BIOSURGERY MARKET FOR STAPLE-LINE REINFORCEMENT AGENTS, BY COUNTRY, 2023-2030 (USD MILLION) 143
TABLE 73 BIOSURGERY MARKET FOR SOFT-TISSUE ATTCHMENTS, BY TYPE,
2023-2030 (USD MILLION) 144
TABLE 74 BIOSURGERY MARKET FOR SOFT-TISSUE ATTCHMENTS, BY COUNTRY,
2023-2030 (USD MILLION) 144
TABLE 75 MAJOR SYNTHETIC MESHES AVAILABLE IN MARKET 145
TABLE 76 SYNTHETIC MESHES MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 146
TABLE 77 MAJOR BIOLOGICAL MESHES AVAILABLE IN MARKET 147
TABLE 78 BIOLOGICAL MESHES MARKET, BY TYPE, 2023-2030 (USD MILLION) 147
TABLE 79 BIOLOGICAL MESHES MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 148
TABLE 80 ALLOGRAFTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 149
TABLE 81 XENOGRAFTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 150
TABLE 82 MAJOR HEMOSTATIC AGENTS AVAILABLE IN MARKET 151
TABLE 83 BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,
2023-2030 (USD MILLION) 151
TABLE 84 BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY COUNTRY,
2023-2030 (USD MILLION) 152
TABLE 85 MAJOR THROMBIN-BASED HEMOSTATIC AGENTS AVAILABLE IN MARKET 153
TABLE 86 THROMBIN-BASED HEMOSTATIC AGENTS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 153
TABLE 87 MAJOR OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATIC AGENTS AVAILABLE IN MARKET 154
TABLE 88 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATIC AGENTS MARKET,
BY COUNTRY, 2023-2030 (USD MILLION) 155
TABLE 89 MAJOR COMBINATION HEMOSTATIC AGENTS AVAILABLE IN MARKET 156
TABLE 90 COMBINATION HEMOSTATIC AGENTS MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 156
TABLE 91 BIOSURGERY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 158
TABLE 92 BIOSURGERY MARKET FOR ORTHOPEDIC SURGERY, BY COUNTRY,
2023-2030 (USD MILLION) 160
TABLE 93 BIOSURGERY MARKET FOR GENERAL SURGERY, BY COUNTRY,
2023-2030 (USD MILLION) 161
TABLE 94 BIOSURGERY MARKET FOR NEUROLOGICAL SURGERY, BY COUNTRY,
2023-2030 (USD MILLION) 163
TABLE 95 BIOSURGERY MARKET FOR CARDIOVASCULAR SURGERY, BY COUNTRY,
2023-2030 (USD MILLION) 164
TABLE 96 BIOSURGERY MARKET FOR RECONSTRUCTIVE SURGERY, BY COUNTRY,
2023-2030 (USD MILLION) 166
TABLE 97 BIOSURGERY MARKET FOR GYNECOLOGICAL SURGERY, BY COUNTRY,
2023-2030 (USD MILLION) 167
TABLE 98 BIOSURGERY MARKET FOR UROLOGICAL SURGERY, BY COUNTRY,
2023-2030 (USD MILLION) 169
TABLE 99 BIOSURGERY MARKET FOR THORACIC SURGERY, BY COUNTRY,
2023-2030 (USD MILLION) 170
TABLE 100 BIOSURGERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2023-2030 (USD MILLION) 172
TABLE 101 BIOSURGERY MARKET, BY END USER, 2023-2030 (USD MILLION) 174
TABLE 102 BIOSURGERY MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION) 176
TABLE 103 BIOSURGERY MARKET FOR CLINICS, BY COUNTRY, 2023-2030 (USD MILLION) 177
TABLE 104 BIOSURGERY MARKET FOR AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2023-2030 (USD MILLION) 178
TABLE 105 BIOSURGERY MARKET FOR OTHER END USERS, BY COUNTRY,
2023-2030 (USD MILLION) 179
TABLE 106 BIOSURGERY MARKET, BY REGION, 2023-2030 (USD MILLION) 182
TABLE 107 NORTH AMERICA: BIOSURGERY MARKET, BY COUNTRY,
2023-2030 (USD MILLION) 183
TABLE 108 NORTH AMERICA: BIOSURGERY MARKET, BY PRODUCT,
2023-2030 (USD MILLION) 184
TABLE 109 NORTH AMERICA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES,
BY TYPE, 2023-2030 (USD MILLION) 184
TABLE 110 NORTH AMERICA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023-2030 (USD MILLION) 185
TABLE 111 NORTH AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 185
TABLE 112 NORTH AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023-2030 (USD MILLION) 186
TABLE 113 NORTH AMERICA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 186
TABLE 114 NORTH AMERICA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023-2030 (USD MILLION) 186
TABLE 115 NORTH AMERICA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 187
TABLE 116 NORTH AMERICA: NATURAL ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 187
TABLE 117 NORTH AMERICA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS,
BY TYPE, 2023-2030 (USD MILLION) 187
TABLE 118 NORTH AMERICA: BIOLOGICAL MESHES MARKET, BY TYPE,
2023-2030 (USD MILLION) 188
TABLE 119 NORTH AMERICA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023-2030 (USD MILLION) 188
TABLE 120 NORTH AMERICA: BIOSURGERY MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 188
TABLE 121 NORTH AMERICA: BIOSURGERY MARKET, BY END USER,
2023-2030 (USD MILLION) 189
TABLE 122 US: BIOSURGERY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 190
TABLE 123 US: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,
2023-2030 (USD MILLION) 190
TABLE 124 US: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023-2030 (USD MILLION) 191
TABLE 125 US: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 191
TABLE 126 US: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY ORIGIN, 2023-2030 (USD MILLION) 192
TABLE 127 US: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 192
TABLE 128 US: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,
2023-2030 (USD MILLION) 192
TABLE 129 US: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 193
TABLE 130 US: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 193
TABLE 131 US: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE,
2023-2030 (USD MILLION) 193
TABLE 132 US: BIOLOGICAL MESHES MARKET, BY TYPE, 2023-2030 (USD MILLION) 194
TABLE 133 US: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,
2023-2030 (USD MILLION) 194
TABLE 134 US: BIOSURGERY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 194
TABLE 135 US: BIOSURGERY MARKET, BY END USER, 2023-2030 (USD MILLION) 195
TABLE 136 CANADA: BIOSURGERY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 195
TABLE 137 CANADA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,
2023-2030 (USD MILLION) 196
TABLE 138 CANADA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023-2030 (USD MILLION) 196
TABLE 139 CANADA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY TYPE, 2023-2030 (USD MILLION) 197
TABLE 140 CANADA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY ORIGIN, 2023-2030 (USD MILLION) 197
TABLE 141 CANADA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 198
TABLE 142 CANADA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,
2023-2030 (USD MILLION) 198
TABLE 143 CANADA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 198
TABLE 144 CANADA: NATURAL ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 199
TABLE 145 CANADA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023-2030 (USD MILLION) 199
TABLE 146 CANADA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023-2030 (USD MILLION) 199
TABLE 147 CANADA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,
2023-2030 (USD MILLION) 200
TABLE 148 CANADA: BIOSURGERY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 200
TABLE 149 CANADA: BIOSURGERY MARKET, BY END USER, 2023-2030 (USD MILLION) 201
TABLE 150 EUROPE: BIOSURGERY MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 201
TABLE 151 EUROPE: BIOSURGERY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 202
TABLE 152 EUROPE: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,
2023-2030 (USD MILLION) 202
TABLE 153 EUROPE: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023-2030 (USD MILLION) 203
TABLE 154 EUROPE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY TYPE, 2023-2030 (USD MILLION) 203
TABLE 155 EUROPE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY ORIGIN, 2023-2030 (USD MILLION) 204
TABLE 156 EUROPE: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 204
TABLE 157 EUROPE: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,
2023-2030 (USD MILLION) 204
TABLE 158 EUROPE: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 205
TABLE 159 EUROPE: NATURAL ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 205
TABLE 160 EUROPE: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023-2030 (USD MILLION) 205
TABLE 161 EUROPE: BIOLOGICAL MESHES MARKET, BY TYPE, 2023-2030 (USD MILLION) 206
TABLE 162 EUROPE: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,
2023-2030 (USD MILLION) 206
TABLE 163 EUROPE: BIOSURGERY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 206
TABLE 164 EUROPE: BIOSURGERY MARKET, BY END USER, 2023-2030 (USD MILLION) 207
TABLE 165 GERMANY: BIOSURGERY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 208
TABLE 166 GERMANY: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023-2030 (USD MILLION) 208
TABLE 167 GERMANY: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES,
BY TYPE, 2023-2030 (USD MILLION) 208
TABLE 168 GERMANY: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY TYPE, 2023-2030 (USD MILLION) 209
TABLE 169 GERMANY: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY ORIGIN, 2023-2030 (USD MILLION) 209
TABLE 170 GERMANY: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 210
TABLE 171 GERMANY: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,
2023-2030 (USD MILLION) 210
TABLE 172 GERMANY: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 210
TABLE 173 GERMANY: NATURAL ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 211
TABLE 174 GERMANY: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023-2030 (USD MILLION) 211
TABLE 175 GERMANY: BIOLOGICAL MESHES MARKET, BY TYPE, 2023-2030 (USD MILLION) 211
TABLE 176 GERMANY: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,
2023-2030 (USD MILLION) 212
TABLE 177 GERMANY: BIOSURGERY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 212
TABLE 178 GERMANY: BIOSURGERY MARKET, BY END USER, 2023-2030 (USD MILLION) 213
TABLE 179 UK: BIOSURGERY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 213
TABLE 180 UK: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,
2023-2030 (USD MILLION) 214
TABLE 181 UK: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023-2030 (USD MILLION) 214
TABLE 182 UK: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 215
TABLE 183 UK: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY ORIGIN, 2023-2030 (USD MILLION) 215
TABLE 184 UK: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 216
TABLE 185 UK: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,
2023-2030 (USD MILLION) 216
TABLE 186 UK: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 216
TABLE 187 UK: NATURAL ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 217
TABLE 188 UK: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE,
2023-2030 (USD MILLION) 217
TABLE 189 UK: BIOLOGICAL MESHES MARKET, BY TYPE, 2023-2030 (USD MILLION) 217
TABLE 190 UK: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,
2023-2030 (USD MILLION) 218
TABLE 191 UK: BIOSURGERY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 218
TABLE 192 UK: BIOSURGERY MARKET, BY END USER, 2023-2030 (USD MILLION) 219
TABLE 193 FRANCE: BIOSURGERY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 219
TABLE 194 FRANCE: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,
2023-2030 (USD MILLION) 220
TABLE 195 FRANCE: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023-2030 (USD MILLION) 220
TABLE 196 FRANCE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY TYPE, 2023-2030 (USD MILLION) 221
TABLE 197 FRANCE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY ORIGIN, 2023-2030 (USD MILLION) 221
TABLE 198 FRANCE: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 222
TABLE 199 FRANCE: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,
2023-2030 (USD MILLION) 222
TABLE 200 FRANCE: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 222
TABLE 201 FRANCE: NATURAL ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 223
TABLE 202 FRANCE: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023-2030 (USD MILLION) 223
TABLE 203 FRANCE: BIOLOGICAL MESHES MARKET, BY TYPE, 2023-2030 (USD MILLION) 223
TABLE 204 FRANCE: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,
2023-2030 (USD MILLION) 224
TABLE 205 FRANCE: BIOSURGERY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 224
TABLE 206 FRANCE: BIOSURGERY MARKET, BY END USER, 2023-2030 (USD MILLION) 225
TABLE 207 ITALY: BIOSURGERY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 225
TABLE 208 ITALY: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,
2023-2030 (USD MILLION) 226
TABLE 209 ITALY: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023-2030 (USD MILLION) 226
TABLE 210 ITALY: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY TYPE, 2023-2030 (USD MILLION) 227
TABLE 211 ITALY: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY ORIGIN, 2023-2030 (USD MILLION) 227
TABLE 212 ITALY: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 228
TABLE 213 ITALY: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,
2023-2030 (USD MILLION) 228
TABLE 214 ITALY: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 228
TABLE 215 ITALY: NATURAL ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 229
TABLE 216 ITALY: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE,
2023-2030 (USD MILLION) 229
TABLE 217 ITALY: BIOLOGICAL MESHES MARKET, BY TYPE, 2023-2030 (USD MILLION) 229
TABLE 218 ITALY: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,
2023-2030 (USD MILLION) 230
TABLE 219 ITALY: BIOSURGERY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 230
TABLE 220 ITALY: BIOSURGERY MARKET, BY END USER, 2023-2030 (USD MILLION) 231
TABLE 221 SPAIN: BIOSURGERY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 231
TABLE 222 SPAIN: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,
2023-2030 (USD MILLION) 232
TABLE 223 SPAIN: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023-2030 (USD MILLION) 232
TABLE 224 SPAIN: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY TYPE, 2023-2030 (USD MILLION) 233
TABLE 225 SPAIN: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY ORIGIN, 2023-2030 (USD MILLION) 233
TABLE 226 SPAIN: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 234
TABLE 227 SPAIN: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,
2023-2030 (USD MILLION) 234
TABLE 228 SPAIN: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 235
TABLE 229 SPAIN: NATURAL ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 235
TABLE 230 SPAIN: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE,
2023-2030 (USD MILLION) 235
TABLE 231 SPAIN: BIOLOGICAL MESHES MARKET, BY TYPE, 2023-2030 (USD MILLION) 236
TABLE 232 SPAIN: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,
2023-2030 (USD MILLION) 236
TABLE 233 SPAIN: BIOSURGERY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 236
TABLE 234 SPAIN: BIOSURGERY MARKET, BY END USER, 2023-2030 (USD MILLION) 237
TABLE 235 REST OF EUROPE: BIOSURGERY MARKET, BY PRODUCT,
2023-2030 (USD MILLION) 237
TABLE 236 REST OF EUROPE: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES,
BY TYPE, 2023-2030 (USD MILLION) 238
TABLE 237 REST OF EUROPE: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023-2030 (USD MILLION) 238
TABLE 238 REST OF EUROPE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 239
TABLE 239 REST OF EUROPE: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023-2030 (USD MILLION) 239
TABLE 240 REST OF EUROPE: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 240
TABLE 241 REST OF EUROPE: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023-2030 (USD MILLION) 240
TABLE 242 REST OF EUROPE: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 241
TABLE 243 REST OF EUROPE: NATURAL ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 241
TABLE 244 REST OF EUROPE: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS,
BY TYPE, 2023-2030 (USD MILLION) 241
TABLE 245 REST OF EUROPE: BIOLOGICAL MESHES MARKET, BY TYPE,
2023-2030 (USD MILLION) 242
TABLE 246 REST OF EUROPE: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023-2030 (USD MILLION) 242
TABLE 247 REST OF EUROPE: BIOSURGERY MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 242
TABLE 248 REST OF EUROPE: BIOSURGERY MARKET, BY END USER,
2023-2030 (USD MILLION) 243
TABLE 249 ASIA PACIFIC: BIOSURGERY MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 245
TABLE 250 ASIA PACIFIC: BIOSURGERY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 245
TABLE 251 ASIA PACIFIC: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023-2030 (USD MILLION) 246
TABLE 252 ASIA PACIFIC: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES,
BY TYPE, 2023-2030 (USD MILLION) 246
TABLE 253 ASIA PACIFIC: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 247
TABLE 254 ASIA PACIFIC: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023-2030 (USD MILLION) 247
TABLE 255 ASIA PACIFIC: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 248
TABLE 256 ASIA PACIFIC: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,
2023-2030 (USD MILLION) 248
TABLE 257 ASIA PACIFIC: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 249
TABLE 258 ASIA PACIFIC: NATURAL ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 249
TABLE 259 ASIA PACIFIC: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023-2030 (USD MILLION) 249
TABLE 260 ASIA PACIFIC: BIOLOGICAL MESHES MARKET, BY TYPE, 2023-2030 (USD MILLION) 250
TABLE 261 ASIA PACIFIC: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,
2023-2030 (USD MILLION) 250
TABLE 262 ASIA PACIFIC: BIOSURGERY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 250
TABLE 263 ASIA PACIFIC: BIOSURGERY MARKET, BY END USER, 2023-2030 (USD MILLION) 251
TABLE 264 CHINA: BIOSURGERY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 252
TABLE 265 CHINA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,
2023-2030 (USD MILLION) 252
TABLE 266 CHINA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023-2030 (USD MILLION) 252
TABLE 267 CHINA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY TYPE, 2023-2030 (USD MILLION) 253
TABLE 268 CHINA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY ORIGIN, 2023-2030 (USD MILLION) 253
TABLE 269 CHINA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 254
TABLE 270 CHINA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,
2023-2030 (USD MILLION) 254
TABLE 271 CHINA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 254
TABLE 272 CHINA: NATURAL ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 255
TABLE 273 CHINA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE,
2023-2030 (USD MILLION) 255
TABLE 274 CHINA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023-2030 (USD MILLION) 255
TABLE 275 CHINA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,
2023-2030 (USD MILLION) 256
TABLE 276 CHINA: BIOSURGERY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 256
TABLE 277 CHINA: BIOSURGERY MARKET, BY END USER, 2023-2030 (USD MILLION) 257
TABLE 278 INDIA: BIOSURGERY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 257
TABLE 279 INDIA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,
2023-2030 (USD MILLION) 258
TABLE 280 INDIA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023-2030 (USD MILLION) 258
TABLE 281 INDIA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY TYPE, 2023-2030 (USD MILLION) 259
TABLE 282 INDIA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY ORIGIN, 2023-2030 (USD MILLION) 259
TABLE 283 INDIA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 260
TABLE 284 INDIA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,
2023-2030 (USD MILLION) 260
TABLE 285 INDIA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 260
TABLE 286 INDIA: NATURAL ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 261
TABLE 287 INDIA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE,
2023-2030 (USD MILLION) 261
TABLE 288 INDIA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023-2030 (USD MILLION) 261
TABLE 289 INDIA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,
2023-2030 (USD MILLION) 262
TABLE 290 INDIA: BIOSURGERY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 262
TABLE 291 INDIA: BIOSURGERY MARKET, BY END USER, 2023-2030 (USD MILLION) 263
TABLE 292 JAPAN: BIOSURGERY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 263
TABLE 293 JAPAN: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,
2023-2030 (USD MILLION) 264
TABLE 294 JAPAN: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023-2030 (USD MILLION) 264
TABLE 295 JAPAN: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY TYPE, 2023-2030 (USD MILLION) 265
TABLE 296 JAPAN: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY ORIGIN, 2023-2030 (USD MILLION) 265
TABLE 297 JAPAN: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 266
TABLE 298 JAPAN: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,
2023-2030 (USD MILLION) 266
TABLE 299 JAPAN: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 266
TABLE 300 JAPAN: NATURAL ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 267
TABLE 301 JAPAN: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE,
2023-2030 (USD MILLION) 267
TABLE 302 JAPAN: BIOLOGICAL MESHES MARKET, BY TYPE, 2023-2030 (USD MILLION) 267
TABLE 303 JAPAN: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,
2023-2030 (USD MILLION) 268
TABLE 304 JAPAN: BIOSURGERY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 268
TABLE 305 JAPAN: BIOSURGERY MARKET, BY END USER, 2023-2030 (USD MILLION) 269
TABLE 306 SOUTH KOREA: BIOSURGERY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 269
TABLE 307 SOUTH KOREA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023-2030 (USD MILLION) 270
TABLE 308 SOUTH KOREA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES,
BY TYPE, 2023-2030 (USD MILLION) 270
TABLE 309 SOUTH KOREA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 271
TABLE 310 SOUTH KOREA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023-2030 (USD MILLION) 271
TABLE 311 SOUTH KOREA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 272
TABLE 312 SOUTH KOREA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,
2023-2030 (USD MILLION) 272
TABLE 313 SOUTH KOREA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 273
TABLE 314 SOUTH KOREA: NATURAL ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 273
TABLE 315 SOUTH KOREA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023-2030 (USD MILLION) 273
TABLE 316 SOUTH KOREA: BIOLOGICAL MESHES MARKET, BY TYPE,
2023-2030 (USD MILLION) 274
TABLE 317 SOUTH KOREA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,
2023-2030 (USD MILLION) 274
TABLE 318 SOUTH KOREA: BIOSURGERY MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 274
TABLE 319 SOUTH KOREA: BIOSURGERY MARKET, BY END USER, 2023-2030 (USD MILLION) 275
TABLE 320 AUSTRALIA: BIOSURGERY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 275
TABLE 321 AUSTRALIA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023-2030 (USD MILLION) 276
TABLE 322 AUSTRALIA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023-2030 (USD MILLION) 276
TABLE 323 AUSTRALIA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 277
TABLE 324 AUSTRALIA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023-2030 (USD MILLION) 277
TABLE 325 AUSTRALIA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 278
TABLE 326 AUSTRALIA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,
2023-2030 (USD MILLION) 278
TABLE 327 AUSTRALIA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 278
TABLE 328 AUSTRALIA: NATURAL ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 279
TABLE 329 AUSTRALIA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023-2030 (USD MILLION) 279
TABLE 330 AUSTRALIA: BIOLOGICAL MESHES MARKET, BY TYPE, 2023-2030 (USD MILLION) 279
TABLE 331 AUSTRALIA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,
2023-2030 (USD MILLION) 280
TABLE 332 AUSTRALIA: BIOSURGERY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 280
TABLE 333 AUSTRALIA: BIOSURGERY MARKET, BY END USER, 2023-2030 (USD MILLION) 281
TABLE 334 REST OF ASIA PACIFIC: BIOSURGERY MARKET, BY PRODUCT,
2023-2030 (USD MILLION) 281
TABLE 335 REST OF ASIA PACIFIC: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES,
BY TYPE, 2023-2030 (USD MILLION) 282
TABLE 336 REST OF ASIA PACIFIC: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023-2030 (USD MILLION) 282
TABLE 337 REST OF ASIA PACIFIC: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 283
TABLE 338 REST OF ASIA PACIFIC: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023-2030 (USD MILLION) 283
TABLE 339 REST OF ASIA PACIFIC: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 284
TABLE 340 REST OF ASIA PACIFIC: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023-2030 (USD MILLION) 284
TABLE 341 REST OF ASIA PACIFIC: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 285
TABLE 342 REST OF ASIA PACIFIC: NATURAL ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 285
TABLE 343 REST OF ASIA PACIFIC: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023-2030 (USD MILLION) 285
TABLE 344 REST OF ASIA PACIFIC: BIOLOGICAL MESHES MARKET, BY TYPE,
2023-2030 (USD MILLION) 286
TABLE 345 REST OF ASIA PACIFIC: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023-2030 (USD MILLION) 286
TABLE 346 REST OF ASIA PACIFIC: BIOSURGERY MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 287
TABLE 347 REST OF ASIA PACIFIC: BIOSURGERY MARKET, BY END USER,
2023-2030 (USD MILLION) 287
TABLE 348 LATIN AMERICA: BIOSURGERY MARKET, BY COUNTRY, 2023-2030 (USD MILLION) 288
TABLE 349 LATIN AMERICA: BIOSURGERY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 289
TABLE 350 LATIN AMERICA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023-2030 (USD MILLION) 289
TABLE 351 LATIN AMERICA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023-2030 (USD MILLION) 290
TABLE 352 LATIN AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 290
TABLE 353 LATIN AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023-2030 (USD MILLION) 291
TABLE 354 LATIN AMERICA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 291
TABLE 355 LATIN AMERICA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023-2030 (USD MILLION) 291
TABLE 356 LATIN AMERICA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 292
TABLE 357 LATIN AMERICA: NATURAL ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 292
TABLE 358 LATIN AMERICA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023-2030 (USD MILLION) 292
TABLE 359 LATIN AMERICA: BIOLOGICAL MESHES MARKET, BY TYPE,
2023-2030 (USD MILLION) 293
TABLE 360 LATIN AMERICA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023-2030 (USD MILLION) 293
TABLE 361 LATIN AMERICA: BIOSURGERY MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 293
TABLE 362 LATIN AMERICA: BIOSURGERY MARKET, BY END USER,
2023-2030 (USD MILLION) 294
TABLE 363 BRAZIL: BIOSURGERY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 294
TABLE 364 BRAZIL: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,
2023-2030 (USD MILLION) 295
TABLE 365 BRAZIL: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023-2030 (USD MILLION) 295
TABLE 366 BRAZIL: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY TYPE, 2023-2030 (USD MILLION) 296
TABLE 367 BRAZIL: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY ORIGIN, 2023-2030 (USD MILLION) 296
TABLE 368 BRAZIL: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 297
TABLE 369 BRAZIL: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,
2023-2030 (USD MILLION) 297
TABLE 370 BRAZIL: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 298
TABLE 371 BRAZIL: NATURAL ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 298
TABLE 372 BRAZIL: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE,
2023-2030 (USD MILLION) 298
TABLE 373 BRAZIL: BIOLOGICAL MESHES MARKET, BY TYPE, 2023-2030 (USD MILLION) 299
TABLE 374 BRAZIL: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,
2023-2030 (USD MILLION) 299
TABLE 375 BRAZIL: BIOSURGERY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 299
TABLE 376 BRAZIL: BIOSURGERY MARKET, BY END USER, 2023-2030 (USD MILLION) 300
TABLE 377 MEXICO: BIOSURGERY MARKET, BY PRODUCT, 2023-2030 (USD MILLION) 300
TABLE 378 MEXICO: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE,
2023-2030 (USD MILLION) 301
TABLE 379 MEXICO: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023-2030 (USD MILLION) 301
TABLE 380 MEXICO: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY TYPE, 2023-2030 (USD MILLION) 302
TABLE 381 MEXICO: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET,
BY ORIGIN, 2023-2030 (USD MILLION) 302
TABLE 382 MEXICO: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 303
TABLE 383 MEXICO: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE,
2023-2030 (USD MILLION) 303
TABLE 384 MEXICO: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 303
TABLE 385 MEXICO: NATURAL ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 304
TABLE 386 MEXICO: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE,
2023-2030 (USD MILLION) 304
TABLE 387 MEXICO: BIOLOGICAL MESHES MARKET, BY TYPE, 2023-2030 (USD MILLION) 304
TABLE 388 MEXICO: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE,
2023-2030 (USD MILLION) 305
TABLE 389 MEXICO: BIOSURGERY MARKET, BY APPLICATION, 2023-2030 (USD MILLION) 305
TABLE 390 MEXICO: BIOSURGERY MARKET, BY END USER, 2023-2030 (USD MILLION) 306
TABLE 391 REST OF LATIN AMERICA: BIOSURGERY MARKET, BY PRODUCT,
2023-2030 (USD MILLION) 306
TABLE 392 REST OF LATIN AMERICA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023-2030 (USD MILLION) 307
TABLE 393 REST OF LATIN AMERICA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023-2030 (USD MILLION) 307
TABLE 394 REST OF LATIN AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 308
TABLE 395 REST OF LATIN AMERICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023-2030 (USD MILLION) 308
TABLE 396 REST OF LATIN AMERICA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 309
TABLE 397 REST OF LATIN AMERICA: BIOSURGERY MARKET FOR ADHESION BARRIERS,
BY TYPE, 2023-2030 (USD MILLION) 309
TABLE 398 REST OF LATIN AMERICA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 310
TABLE 399 REST OF LATIN AMERICA: NATURAL ADHESION BARRIERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 310
TABLE 400 REST OF LATIN AMERICA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023-2030 (USD MILLION) 310
TABLE 401 REST OF LATIN AMERICA: BIOLOGICAL MESHES MARKET, BY TYPE,
2023-2030 (USD MILLION) 311
TABLE 402 REST OF LATIN AMERICA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS,
BY TYPE, 2023-2030 (USD MILLION) 311
TABLE 403 REST OF LATIN AMERICA: BIOSURGERY MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 312
TABLE 404 REST OF LATIN AMERICA: BIOSURGERY MARKET, BY END USER,
2023-2030 (USD MILLION) 312
TABLE 405 MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY REGION,
2023-2030 (USD MILLION) 313
TABLE 406 MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY PRODUCT,
2023-2030 (USD MILLION) 314
TABLE 407 MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023-2030 (USD MILLION) 314
TABLE 408 MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023-2030 (USD MILLION) 315
TABLE 409 MIDDLE EAST & AFRICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 315
TABLE 410 MIDDLE EAST & AFRICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023-2030 (USD MILLION) 316
TABLE 411 MIDDLE EAST & AFRICA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 316
TABLE 412 MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR ADHESION BARRIERS,
BY TYPE, 2023-2030 (USD MILLION) 316
TABLE 413 MIDDLE EAST & AFRICA: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE, 2023-2030 (USD MILLION) 317
TABLE 414 MIDDLE EAST & AFRICA: NATURAL ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 317
TABLE 415 MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023-2030 (USD MILLION) 317
TABLE 416 MIDDLE EAST & AFRICA: BIOLOGICAL MESHES MARKET, BY TYPE,
2023-2030 (USD MILLION) 318
TABLE 417 MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS,
BY TYPE, 2023-2030 (USD MILLION) 318
TABLE 418 MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 319
TABLE 419 MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY END USER,
2023-2030 (USD MILLION) 319
TABLE 420 GCC COUNTRIES: BIOSURGERY MARKET, BY PRODUCT,
2023-2030 (USD MILLION) 320
TABLE 421 GCC COUNTRIES: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023-2030 (USD MILLION) 320
TABLE 422 GCC COUNTRIES: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023-2030 (USD MILLION) 321
TABLE 423 GCC COUNTRIES: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 321
TABLE 424 GCC COUNTRIES: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023-2030 (USD MILLION) 322
TABLE 425 GCC COUNTRIES: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 322
TABLE 426 GCC COUNTRIES: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023-2030 (USD MILLION) 322
TABLE 427 GCC COUNTRIES: SYNTHETIC ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 323
TABLE 428 GCC COUNTRIES: NATURAL ADHESION BARRIERS MARKET, BY TYPE,
2023-2030 (USD MILLION) 323
TABLE 429 GCC COUNTRIES: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS,
BY TYPE, 2023-2030 (USD MILLION) 323
TABLE 430 GCC COUNTRIES: BIOLOGICAL MESHES MARKET, BY TYPE,
2023-2030 (USD MILLION) 324
TABLE 431 GCC COUNTRIES: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023-2030 (USD MILLION) 324
TABLE 432 GCC COUNTRIES: BIOSURGERY MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 324
TABLE 433 GCC COUNTRIES: BIOSURGERY MARKET, BY END USER,
2023-2030 (USD MILLION) 325
TABLE 434 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY PRODUCT,
2023-2030 (USD MILLION) 325
TABLE 435 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR BONE-GRAFT SUBSTITUTES, BY TYPE, 2023-2030 (USD MILLION) 326
TABLE 436 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR SURGICAL SEALANTS & ADHESIVES, BY TYPE, 2023-2030 (USD MILLION) 326
TABLE 437 REST OF MIDDLE EAST & AFRICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 327
TABLE 438 REST OF MIDDLE EAST & AFRICA: NATURAL/BIOLOGICAL SURGICAL SEALANTS & ADHESIVES MARKET, BY ORIGIN, 2023-2030 (USD MILLION) 327
TABLE 439 REST OF MIDDLE EAST & AFRICA: SYNTHETIC & SEMI-SYNTHETIC SURGICAL SEALANTS & ADHESIVES MARKET, BY TYPE, 2023-2030 (USD MILLION) 328
TABLE 440 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR ADHESION BARRIERS, BY TYPE, 2023-2030 (USD MILLION) 328
TABLE 441 REST OF MIDDLE EAST & AFRICA: SYNTHETIC ADHESION BARRIERS MARKET,
BY TYPE, 2023-2030 (USD MILLION) 329
TABLE 442 REST OF MIDDLE EAST & AFRICA: NATURAL ADHESION BARRIERS MARKET,
BY TYPE, 2023-2030 (USD MILLION) 329
TABLE 443 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR SOFT-TISSUE ATTACHMENTS, BY TYPE, 2023-2030 (USD MILLION) 329
TABLE 444 REST OF MIDDLE EAST & AFRICA: BIOLOGICAL MESHES MARKET, BY TYPE,
2023-2030 (USD MILLION) 330
TABLE 445 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET FOR HEMOSTATIC AGENTS, BY TYPE, 2023-2030 (USD MILLION) 330
TABLE 446 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY APPLICATION,
2023-2030 (USD MILLION) 331
TABLE 447 REST OF MIDDLE EAST & AFRICA: BIOSURGERY MARKET, BY END USER,
2023-2030 (USD MILLION) 331
TABLE 448 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN BIOSURGERY MARKET 332
TABLE 449 BIOSURGERY MARKET: DEGREE OF COMPETITION 335
TABLE 450 BIOSURGERY MARKET: REGION FOOTPRINT 339
TABLE 451 BIOSURGERY MARKET: PRODUCT FOOTPRINT 340
TABLE 452 BIOSURGERY MARKET: APPLICATION FOOTPRINT 341
TABLE 453 BIOSURGERY MARKET: END-USER FOOTPRINT 342
TABLE 454 BIOSURGERY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 345
TABLE 455 BIOSURGERY MARKET: COMPETITIVE BENCHMARKING OF KEY
STARTUPS/SME PLAYERS, BY PRODUCT AND REGION 346
TABLE 456 BIOSURGERY MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022-JUNE 2025 348
TABLE 457 BIOSURGERY MARKET: DEALS, JANUARY 2022-JUNE 2025 349
TABLE 458 BAXTER: COMPANY OVERVIEW 350
TABLE 459 BAXTER: PRODUCTS OFFERED 351
TABLE 460 B BRAUN SE: COMPANY OVERVIEW 354
TABLE 461 B BRAUN SE: PRODUCTS OFFERED 355
TABLE 462 BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW 357
TABLE 463 BECTON, DICKINSON AND COMPANY (BD): PRODUCTS OFFERED 358
TABLE 464 JOHNSON & JOHNSON: COMPANY OVERVIEW 361
TABLE 465 JOHNSON & JOHNSON: PRODUCTS OFFERED 362
TABLE 466 MEDTRONIC: COMPANY OVERVIEW 365
TABLE 467 MEDTRONIC: PRODUCTS OFFERED 366
TABLE 468 INTEGRA LIFESCIENCES CORPORATION: COMPANY OVERVIEW 369
TABLE 469 INTEGRA LIFESCIENCES CORPORATION: PRODUCTS OFFERED 370
TABLE 470 COMMONWEALTH SERUM LABORATORIES LIMITED (CSL): COMPANY OVERVIEW 372
TABLE 471 COMMONWEALTH SERUM LABORATORIES LIMITED (CSL): PRODUCTS OFFERED 373
TABLE 472 HEMOSTASIS, LLC: COMPANY OVERVIEW 374
TABLE 473 HEMOSTASIS, LLC: PRODUCTS OFFERED 374
TABLE 474 PFIZER INC.: COMPANY OVERVIEW 375
TABLE 475 PFIZER INC.: PRODUCTS OFFERED 376
TABLE 476 STRYKER: COMPANY OVERVIEW 377
TABLE 477 STRYKER: PRODUCTS OFFERED 378
TABLE 478 ARTIVION, INC.: COMPANY OVERVIEW 380
TABLE 479 ARTIVION, INC.: PRODUCTS OFFERED 381
TABLE 480 ZIMMER BIOMET: COMPANY OVERVIEW 383
TABLE 481 ZIMMER BIOMET: PRODUCTS OFFERED 384
TABLE 482 ZIMMER BIOMET: DEALS, JANUARY 2022-JUNE 2025 385
TABLE 483 KUROS BIOSCIENCES: COMPANY OVERVIEW 386
TABLE 484 KUROS BIOSCIENCES: PRODUCTS OFFERED 387
TABLE 485 KUROS BIOSCIENCES: PRODUCT APPROVALS, JANUARY 2021-JUNE 2025 387
TABLE 486 KUROS BIOSCIENCES: DEALS, JANUARY 2022-JUNE 2025 388
TABLE 487 ORTHOFIX MEDICAL INC.: COMPANY OVERVIEW 389
TABLE 488 ORTHOFIX MEDICAL INC.: PRODUCTS OFFERED 390
TABLE 489 ORTHOFIX MEDICAL INC.: PRODUCT LAUNCHES, JANUARY 2021-JUNE 2025 391
TABLE 490 ORTHOFIX MEDICAL INC.: DEALS, JANUARY 2022-JUNE 2025 391
TABLE 491 SMITH & NEPHEW: COMPANY OVERVIEW 392
TABLE 492 SMITH & NEPHEW: PRODUCTS OFFERED 393
TABLE 493 TISSUE REGENIX: COMPANY OVERVIEW 394
TABLE 494 BETATECH MEDICAL: COMPANY OVERVIEW 395
TABLE 495 MERIL LIFE SCIENCES PVT. LTD.: COMPANY OVERVIEW 396
TABLE 496 GLOBUS MEDICAL: COMPANY OVERVIEW 397
TABLE 497 SAMYANG HOLDINGS CORPORATION: COMPANY OVERVIEW 398
TABLE 498 AROA BIOSURGERY LIMITED: COMPANY OVERVIEW 399
TABLE 499 MEYER-HAAKE GMBH: COMPANY OVERVIEW 400
TABLE 500 ADVANCED MEDICAL SOLUTIONS GROUP PLC: COMPANY OVERVIEW 401
TABLE 501 BIOCER ENTWICKLUNGS-GMBH: COMPANY OVERVIEW 402
TABLE 502 WILTROM: COMPANY OVERVIEW 403
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security